Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17988304rdf:typepubmed:Citationlld:pubmed
pubmed-article:17988304lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C0019004lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C0079731lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C1521726lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C0205219lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C0278348lld:lifeskim
pubmed-article:17988304lifeskim:mentionsumls-concept:C1518321lld:lifeskim
pubmed-article:17988304pubmed:issue6lld:pubmed
pubmed-article:17988304pubmed:dateCreated2007-11-8lld:pubmed
pubmed-article:17988304pubmed:abstractTextTo date little data exist about treatment of hematologic malignancies in patients with end-stage renal disease (ESRD). While administration of immunochemotherapy comprising the CD20-antibody rituximab is a well-established treatment strategy in patients with normal renal function, little information on safety and efficacy is available in the setting of ESRD. Here we describe for the first time a hemodialysis patient suffering from diffuse large B-cell Non-Hodgkin's lymphoma (DLBCL) who was treated with polychemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in combination with rituximab (R-CHOP). We observed no major adverse events and treatment resulted in a partial remission of the DLBCL. Thus, administration of R-CHOP may be considered as a safe therapeutic option in this setting. Of note, this patient had a previous history of hairy cell leukemia. A review of the literature was performed and the potential etiologic link of these two B-cell malignancies is discussed in the light of available information.lld:pubmed
pubmed-article:17988304pubmed:languageenglld:pubmed
pubmed-article:17988304pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:citationSubsetIMlld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17988304pubmed:statusMEDLINElld:pubmed
pubmed-article:17988304pubmed:monthDeclld:pubmed
pubmed-article:17988304pubmed:issn1751-5521lld:pubmed
pubmed-article:17988304pubmed:authorpubmed-author:FeldmannGGlld:pubmed
pubmed-article:17988304pubmed:authorpubmed-author:GerhardsUUlld:pubmed
pubmed-article:17988304pubmed:authorpubmed-author:WoitasRRlld:pubmed
pubmed-article:17988304pubmed:authorpubmed-author:SpenglerUUlld:pubmed
pubmed-article:17988304pubmed:authorpubmed-author:NattermannJJlld:pubmed
pubmed-article:17988304pubmed:authorpubmed-author:NähleC PCPlld:pubmed
pubmed-article:17988304pubmed:issnTypePrintlld:pubmed
pubmed-article:17988304pubmed:volume29lld:pubmed
pubmed-article:17988304pubmed:ownerNLMlld:pubmed
pubmed-article:17988304pubmed:authorsCompleteYlld:pubmed
pubmed-article:17988304pubmed:pagination469-73lld:pubmed
pubmed-article:17988304pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:meshHeadingpubmed-meshheading:17988304...lld:pubmed
pubmed-article:17988304pubmed:year2007lld:pubmed
pubmed-article:17988304pubmed:articleTitlePartial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP.lld:pubmed
pubmed-article:17988304pubmed:affiliationDepartment of Internal Medicine 1, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany. gfeldma4@jhmi.edulld:pubmed
pubmed-article:17988304pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17988304pubmed:publicationTypeReviewlld:pubmed
pubmed-article:17988304pubmed:publicationTypeCase Reportslld:pubmed